Development of Interleukin-1 Receptor Antagonist Mutants with Enhanced Antagonistic Activity In Vitro and Improved Therapeutic Efficacy in Collagen-Induced Arthritis

REFERENCES

• Arend W. P., Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. 2000; 2: 245–248
   PubMedGoogle Scholar
• Short Protocols in Molecular Biology, F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, K. Struhl. Wiley, Hoboken, NJ 2002
   Google Scholar
• Bodar E. J., van der Hilst J. C., Drenth J. P., van Der Meer J. W., Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth. J. Med. 2005; 63: 260–264
   PubMed Web of Science ®Google Scholar
• Bowen S., Tare N., Inoue T., Yamasaki M., Okabe M., Horii I., Eliason J. F. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 1999; 27: 425–432
   PubMed Web of Science ®Google Scholar
• Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B., Watt I., Williams B., Aitchison R., McCabe D., Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998; 41: 2196–2204
   PubMed Web of Science ®Google Scholar
• Burger D., Dayer J. M., Palmer G., Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best. Pract. Res. Clin. Rheumatol. 2006; 20: 879–896
   PubMed Web of Science ®Google Scholar
• Chae J. J., Wood G., Masters S. L., Richard K., Park G., Smith B. J., Kastner D. L. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. USA 2006; 103: 9982–9987
   PubMed Web of Science ®Google Scholar
• Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M. E., Moreland L. W., Kremer J., Bear M. B., Rich W. J., McCabe D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46: 614–624
   PubMed Web of Science ®Google Scholar
• Cohen S. B., Moreland L. W., Cush J. J., Greenwald M. W., Block S., Shergy W. J., Hanrahan P. S., Kraishi M. M., Patel A., Sun G., Bear M. B. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 2004; 63: 1062–1068
   PubMed Web of Science ®Google Scholar
• Delano. The PyMol Molecular Graphics System. Delano Scientific, San Carlos 2002
   Google Scholar
• Dierselhuis M. P., Frenkel J., Wulffraat N. M., Boelens J. J. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005; 44: 406–408
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. Pro-inflammatory cytokines. Chest 2000; 118: 503–508
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 2002; 20: S1–13
   PubMed Web of Science ®Google Scholar
• Fitzgerald A. A., Leclercq S. A., Yan A., Homik J. E., Dinarello C. A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005; 52: 1794–1803
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R., Dailey N. J., Canna S. W., Gelabert A., Jones J., Rubin B. I., Kim H. J., Brewer C., Zalewski C., Wiggs E., Hill S., Turner M. L., Karp B. I., Aksentijevich I., Pucino F., Penzak S. R., Haverkamp M. H., Stein L., Adams B. S., Moore T. L., Fuhlbrigge R. C., Shaham B., Jarvis J. N., O'Neil K., Vehe R. K., Beitz L. O., Gardner G., Hannan W. P., Warren R. W., Horn W., Cole J. L., Paul S. M., Hawkins P. N., Pham T. H., Snyder C., Wesley R. A., Hoffmann S. C., Holland S. M., Butman J. A., Kastner D. L. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. New Engl. J. Med. 2006; 355: 581–592
   PubMed Web of Science ®Google Scholar
• Hawkins P. N., Bybee A., Aganna E., McDermott M. F. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2004a; 50: 2708–2709
   PubMedGoogle Scholar
• Hawkins P. N., Lachmann H. J., Aganna E., McDermott M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004b; 50: 607–612
   PubMed Web of Science ®Google Scholar
• Hawkins P. N., Lachmann H. J., McDermott M. F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New Engl. J. Med. 2003; 348: 2583–2584
   PubMed Web of Science ®Google Scholar
• Heguy A., Baldari C. T., Macchia G., Telford J. L., Melli M. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila toll protein are essential for IL-1R signal transduction. J. Biol. Chem. 1992; 267: 2605–2609
   PubMedGoogle Scholar
• Hoffman H. M., Firestein G. S. Anakinra for the treatment of neonatal-onset multisystem inflammatory disease. Nat. Clin. Pract. Rheumatol. 2006; 2: 646–647
   PubMedGoogle Scholar
• Hoffman H. M., Rosengren S., Boyle D. L., Cho J. Y., Nayar J., Mueller J. L., Anderson J. P., Wanderer A. A., Firestein G. S. Prevention of cold-associated acute inflammation in familial cold auto-inflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779–1785
   PubMed Web of Science ®Google Scholar
• Joosten L. A., Helsen M. M., Saxne T., van De Loo F. A., Heinegard D., van den Berg W. B. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNFα blockade only ameliorates joint inflammation. J. Immunol. 1999; 163: 5049–5055
   PubMed Web of Science ®Google Scholar
• Larsen C. M., Faulenbach M., Vaag A., Volund A., Ehses J. A., Seifert B., Mandrup-Poulsen T., Donath M. Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl. J. Med. 2007; 356: 1517–1526
   PubMed Web of Science ®Google Scholar
• Nixon R., Bansback N., Brennan A. The efficacy of inhibiting tumour necrosis factor-α and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology 2007; 46: 1140–1147
   PubMed Web of Science ®Google Scholar
• Nuki G., Bresnihan B., Bear M. B., McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46: 2838–2846
   PubMed Web of Science ®Google Scholar
• Paget S. A. Efficacy of anakinra in bone: Comparison to other biologics. Adv. Ther. 2002; 19: 27–39
   PubMed Web of Science ®Google Scholar
• Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005; 201: 1479–1486
   PubMed Web of Science ®Google Scholar
• Patten P. A., Howard R. J., Stemmer W. P. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr. Opin. Biotechnol. 1997; 8: 724–733
   PubMed Web of Science ®Google Scholar
• Radons J., Gabler S., Wesche H., Korherr C., Hofmeister R., Falk W. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J. Biol. Chem. 2002; 277: 16456–16463
   PubMedGoogle Scholar
• Rudinskaya A., Trock D. H. Successful treatment of a patient with refractory adult-onset still disease with anakinra. J. Clin. Rheumatol. 2003; 9: 330–332
   PubMed Web of Science ®Google Scholar
• Ruiz P. J., Masliah E., Doherty T. A., Quach A., Firestein G. S. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann. Rheum. Dis. 2007; 66: 422–423
   PubMedGoogle Scholar
• Schreuder H., Tardif C., Trump-Kallmeyer S., Soffientini A., Sarubbi E., Akeson A., Bowlin T., Yanofsky S., Barrett R. W. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997; 386: 194–200
   PubMedGoogle Scholar
• Stylianou E., O'Neill L. A., Rawlinson L., Edbrooke M. R., Woo P., Saklatvala J. Interleukin-1 induces NF-κ B through its type I but not its type II receptor in lymphocytes. J Biol Chem 1992; 267: 15836–15841
   PubMedGoogle Scholar
• Vasques Godinho F. M., Parreira Santos M. J., Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 2005; 64: 647–648
   PubMed Web of Science ®Google Scholar
• Yuan L., Kurek I., English J., Keenan R. Laboratory-directed protein evolution. Microbiol. Mol. Biol. Rev. 2005; 69: 373–392
   PubMed Web of Science ®Google Scholar